A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia

The isoflavone ME-344 is a potent anti-cancer agent with preclinical and clinical efficacy in solid tumors. Yet, the mechanism of action of ME-344 has not been fully defined and the preclinical efficacy in leukemia has not been established. Therefore, we investigated the anti-leukemic properties and...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeyaraju, Danny V., Hurren, Rose, Wang, Xiaoming, MacLean, Neil, Gronda, Marcela, Shamas-Din, Aisha, Minden, Mark D., Giaever, Guri, Schimmer, Aaron D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226547/
https://www.ncbi.nlm.nih.gov/pubmed/27391350
http://dx.doi.org/10.18632/oncotarget.10446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226547/
https://www.ncbi.nlm.nih.gov/pubmed/27391350
http://dx.doi.org/10.18632/oncotarget.10446

Ejemplares similares